News

BlogsPosts
As Seen In
Pioneer in Both Biotech & Business Left Noteworthy Legacy
To read the full article as it appears on HuffingtonPost.com by contributing editor, Lee Buckler,
BlogsPosts
As Seen In
Exclusive Interview with RepliCel Life Sciences President and CEO Lee Buckler
To read the full article as it appears on SmarterAnalyst.com by Julie Lamb, click here.
BlogsPosts
As Seen In
Promise of Regenerative Medicine Already Upon Us
To read the full article as it appears on HuffingtonPost.com by contributing editor, Lee Buckler,
BlogsPosts
As Seen In
RepliCel Life Sciences gets price target raise at Echelon Wealth Partners
To read the full article as it appears on Cantech Letters by Nick Waddell, click
BlogsPosts
Press Release
RepliCel CEO Provides Company Outlook
A data-rich 2017 positions RepliCel for maturity through the next phase of its product development,
BlogsPosts
As Seen In
Cell therapy: Scientific breakthrough treats signs of ageing
To read the full article as it appears on Cosmetics design-asia.com by Natasha Spencer, click
BlogsPosts
As Seen In
RepliCel, cell therapy companies ready to give you athletic immortality
To read the full article as it appears on Metro News by Matt Burke, click
BlogsPosts
Press Release
United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies
With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to
BlogsPosts
As Seen In
RepliCel Developing Autologous Cell Therapies For Skin, Hair and Tendon Regeneration
To read the full interview as it appears on MedicalResearch.com, click here. (4/22/17)
BlogsPosts
As Seen In
String of Positive Trial Results Boosts RepliCel’s Profile
To read the full article as it appears on thelifesciencesreport.com, click here. (04/12/17)
BlogsPosts
As Seen In
RepliCel – Stem Cell Therapies Using Your Own Cells
To listen to Podcast and View Transcript on Future Tech Podcast, click here
BlogsPosts
As Seen In
Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis (ReaCT)
To read the full study as it appears on ClinicalTrials.gov, click here.
BlogsPosts
Press Release
Positive Results from RepliCel’s RCS-01 Phase I Skin Trial are the Company’s Most Compelling to Date
Interim trial results lead researchers to conclude that the injection of RCS-01 is not only
BlogsPosts
Press Release
RepliCel’s Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems
First-in-human clinical study meets primary endpoint demonstrating product safety and clinical potential for tendon regeneration
BlogsPosts
Press Release
RepliCel’s Phase 1 Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints
Five-year safety data firmly establishes product safety and confirms ongoing clinical and product development strategy VANCOUVER,
BlogsPosts
Press Release
RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization
VANCOUVER, BC – March 7, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”
BlogsPosts
Press Release
RepliCel Life Sciences Announces Re-pricing of Warrants
VANCOUVER, BC – March 6, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
Press Release
RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector
VANCOUVER, BC – February 28, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”
BlogsPosts
Press Release
RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION
BlogsPosts
Press Release
RepliCel Announces European Patents for its Innovative Dermal Injector Technologies
RCI-02, RepliCel’s nearest-term commercial asset, enables game-changing reliability, reproducibility, and programmability of three-dimensional skin

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.